Supplementary Information

Predicting worse survival for newly diagnosed T cell lymphoma based on the decreased baseline CD16-/CD16+ monocyte ratio

Wei Zhang¹, Jing Ruan¹, Daobin Zhou¹*, Xiao Han¹, Yan Zhang¹, Wei Wang¹, Mingqi Ouyang¹

Supplementary Table S1: Hazard ratios of prognostic factors for overall survival in T-NHL

| Risk factor                                           | HR    | 95% CI       | p     |
|-------------------------------------------------------|-------|--------------|-------|
| Overall survival (OS)                                  |       |              |       |
| Age (≥60y vs <60y)                                     | 1.944 | 0.523-7.222  | 0.321 |
| Sex (male vs female)                                   | 1.817 | 0.547-6.038  | 0.330 |
| Stage                                                 | 4.3   | 0.799-23.16  | 0.089 |
| B symptoms (yes vs no)                                | 2.625 | 0.334-20.62  | 0.359 |
| Number of extra nodal sites (>1 vs 0,1)               | 0.913 | 0.294-2.835  | 0.875 |
| ECOG (2,3,4 vs 0,1)                                    | 7.303 | 1.943-27.45  | 0.003 |
| BM involved (yes vs no)                               | 3.614 | 1.135-11.50  | 0.030 |
| LDH elevated (yes vs no)                              | 4.540 | 0.989-20.850 | 0.052 |
| IPI                                                   | 3.58  | 1.767-7.257  | 0.000 |
| CD16-monocyte(X10^9)(>0.3 vs <0.3)                    | 0.252 | 0.075-0.843  | 0.025 |
| CD16-monocytes/CD16+monocytes(>11 vs <11)            | 0.320 | 0.096-1.072  | 0.065 |
| neutrophil/monocytes                                  | 1.023 | 1.006-1.041  | 0.008 |
| neutrophil/monocytes(>12 vs <12)                      | 3.757 | 1.183-11.937 | 0.025 |
| neutrophil/CD16-monocyte                              | 1.015 | 1.004-1.027  | 0.009 |
| neutrophil/CD16-monocytes(>12 vs <12)                | 3.757 | 1.183-11.937 | 0.025 |

Supplementary Table S2: Hazard ratios of prognostic factors for progressive-free survival in T-NHL

| Risk factor                                           | HR    | 95% CI       | p     |
|-------------------------------------------------------|-------|--------------|-------|
| Progression-free survival (PFS)                        |       |              |       |
| Age (≥60y vs <60y)                                     | 0.996 | 0.282-3.527  | 0.997 |
| Sex (male vs female)                                   | 2.563 | 0.898-7.312  | 0.079 |
| Stage                                                 | 3.632 | 1.148-11.49  | 0.028 |
| B symptoms (yes vs no)                                | 1.271 | 0.349-4.636  | 0.716 |
| Number of extra nodal sites (>1 vs 0,1)               | 0.762 | 0.293-1.986  | 0.579 |
### Supplementary Table S3: The basic clinical characteristics of T-NHL patients for multiplexed immunofluorescent staining

| Clinical characteristics                  | number | percentage |
|------------------------------------------|--------|------------|
| Age                                      |        |            |
| <60y                                     | 13     | 76.5%      |
| ≥60y                                     | 4      | 23.5%      |
| Sex                                      |        |            |
| Male                                     | 10     | 58.8%      |
| Female                                   | 7      | 41.2%      |
|subtype                                   |        |            |
| NK/T lymphoma, nasal                     | 7      | 41.2%      |
| PTCL, NOS                                | 2      | 11.8%      |
| ALCL, ALK-                               | 2      | 11.8%      |
| ALCL, ALK+                               | 2      | 11.8%      |
| SPTL                                     | 2      | 11.8%      |
| AITL                                     | 2      | 11.8%      |
| Ann Arbor                                |        |            |
| I–II                                     | 2      | 11.8%      |
| III–IV                                   | 15     | 88.2%      |
| LDH                                      |        |            |
| Normal                                   | 5      | 29.4%      |
| Elevated                                 | 12     | 70.6%      |
| ECOG                                     |        |            |
| 0,1                                      | 11     | 64.7%      |
| 2,3,4                                    | 6      | 35.3%      |
| BM involvement                           |        |            |
| Yes                                      | 3      | 17.6%      |
| no                                       | 14     | 82.4%      |
| Tissue source                            |        |            |
| Lymphoid nodal                           | 3      | 17.6%      |
| Nasal tissue                             | 5      | 29.4%      |
| Cutaneous tissue                         | 5      | 29.4%      |
| Bone marrow                              | 2      | 11.8%      |
| others                                   | 2      | 11.8%      |